| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF03041041 |
| P698 | PubMed publication ID | 14740344 |
| P2093 | author name string | Klaus Diedrich | |
| Olaf Ortmann | |||
| Annika K Schröder | |||
| Jürgen M Weiss | |||
| Sascha Tauchert | |||
| P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome | Q28142499 | ||
| Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
| Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis | Q28257443 | ||
| Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women | Q29013504 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Interactions of insulin-like growth factor-I, insulin and estradiol with GnRH-stimulated luteinizing hormone release from female rat gonadotrophs | Q31928822 | ||
| Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease | Q32086482 | ||
| Cardiovascular consequences of polycystic ovary syndrome | Q33649443 | ||
| Candidate genes in polycystic ovary syndrome | Q34321200 | ||
| Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy | Q34340770 | ||
| The android woman--a risky condition | Q34372211 | ||
| Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women | Q34489447 | ||
| A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills | Q35120058 | ||
| Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus | Q35751121 | ||
| Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome | Q35752347 | ||
| Coronary Heart Disease Risk Factors in Women With Polycystic Ovary Syndrome | Q51587513 | ||
| Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. | Q51604834 | ||
| Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome | Q51607514 | ||
| Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Results from two national samples. | Q51618340 | ||
| Obstetric outcome in women with polycystic ovarian syndrome. | Q54023022 | ||
| Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance | Q54272730 | ||
| Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome | Q67273627 | ||
| Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women | Q67509425 | ||
| Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome | Q67555170 | ||
| Polycystic ovary disease. A risk factor for gestational diabetes? | Q71924999 | ||
| Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome | Q72173084 | ||
| Metabolic regulation of androgen production by human thecal cells in vitro | Q72223987 | ||
| Differential effects of oral glucose-mediated versus intravenous hyperinsulinemia on circulating androgen levels in women | Q72616055 | ||
| Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women | Q73178292 | ||
| High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus | Q74446024 | ||
| Gestational diabetes and neonatal macrosomia in the polycystic ovary syndrome | Q36923699 | ||
| Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance | Q37370271 | ||
| Mortality of women with polycystic ovary syndrome at long-term follow-up | Q39355781 | ||
| Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group | Q39398476 | ||
| Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study | Q39593191 | ||
| The gonadotropic function of insulin | Q39662639 | ||
| Obesity, lipids, cardiovascular risk, and androgen excess | Q40572164 | ||
| Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. | Q40617532 | ||
| Menstrual cycle irregularity and risk for future cardiovascular disease | Q40642270 | ||
| Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome | Q40654256 | ||
| Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus | Q40671792 | ||
| Metformin in management of pregnant insulin-independent diabetics | Q41493866 | ||
| Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1 | Q42440868 | ||
| A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome | Q42460037 | ||
| Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease | Q42472403 | ||
| Selective insulin resistance in the polycystic ovary syndrome | Q42477575 | ||
| Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome | Q42497234 | ||
| Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. | Q42503591 | ||
| Defects in beta-cell function in functional ovarian hyperandrogenism | Q42511979 | ||
| Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia | Q42517167 | ||
| Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome | Q42518054 | ||
| Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. | Q42518346 | ||
| Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome | Q42519459 | ||
| Basal glucose level as an independent predictor of fertilization rate in patients without polycystic ovary syndrome included in an in-vitro fertilization program. | Q42527698 | ||
| Polycystic ovary syndrome is associated with endothelial dysfunction | Q43540411 | ||
| Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives | Q43601812 | ||
| Low grade chronic inflammation in women with polycystic ovarian syndrome | Q43633815 | ||
| Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. | Q43723378 | ||
| Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy | Q43766398 | ||
| Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone | Q43796289 | ||
| Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome | Q43814293 | ||
| Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome | Q43832908 | ||
| Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features | Q44063700 | ||
| Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome | Q44168053 | ||
| Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin | Q44198605 | ||
| Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes | Q44231053 | ||
| Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome | Q44306848 | ||
| Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy | Q44320563 | ||
| Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome | Q44349470 | ||
| Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine | Q44378827 | ||
| Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience | Q44776229 | ||
| Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. | Q44788399 | ||
| Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study | Q44818140 | ||
| Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes | Q44881423 | ||
| The effects of insulin and insulin-like growth factors-I and -II on estradiol production by granulosa cells of polycystic ovaries. | Q45937587 | ||
| Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. | Q50895589 | ||
| The prevalence of polycystic ovaries in women with a history of gestational diabetes. | Q51553418 | ||
| The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. | Q51558611 | ||
| Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. | Q51563371 | ||
| Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. | Q51576091 | ||
| Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. | Q51582445 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | German | Q188 |
| P921 | main subject | polycystic ovary | Q5547896 |
| polycystic ovary syndrome | Q500816 | ||
| insulin resistance | Q1053470 | ||
| P304 | page(s) | 812-821 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Vienna Clinical Weekly | Q15759796 |
| P1476 | title | Insulin resistance in polycystic ovary syndrome | |
| P478 | volume | 115 |
| Q46134754 | Lack of association between interleukin-1a gene (IL-1a) C (-889) T variant and polycystic ovary syndrome in Chinese women | cites work | P2860 |
Search more.